ASTM F 2065 Standard Practice for Testing for Alternative Pathway Complement Activation in Serum by Solid Materials

	Purchase Information Use this form to request purchase information on ASTM online subscriptions. ASTM Collections First Name: Last Name: Email address:

Document ASTM F 2065 is offered by IHS as part of an online subscription. This subscription contains many documents on the same topic.

You may also purchase this document alone from the IHS Standards Store.

ASTM F 2065 Document Information:

Title
Standard Practice for Testing for Alternative Pathway Complement Activation in Serum by Solid Materials

ASTM International

Publication Date:
Nov 10, 2000

Scope:

This practice provides a protocol for rapid, in vitro screening for alternative pathway complement activating properties of solid materials used in the fabrication of medical devices that will contact blood.

This practice is intended to evaluate the acute in vitro alternative pathway complement activating properties of solid materials intended for use in contact with blood. For this practice, “serum” is synonymous with “complement.”

This practice consists of two procedural parts. Procedure A describes exposure of solid materials to a standard lot of C4-deficient guinea pig serum [C4(-)GPS], using 0.1-mL serum per 13 X 100-mm disposable glass test tubes. Sepharose² CL-4B is used as an example of test materials. Procedure B describes assaying the exposed serum for significant functional alternative pathway complement depletion as compared to control samples. The endpoint in procedure B is lysis of rabbit RBC in buffer containing EGTA and excess Mg++.

This practice does not address function, elaboration, or depletion of individual complement components except as optional additional confirmatory information that can be acquired using human serum as the complement source. This practice does not address the use of plasma as a source of complement.

This practice is one of several developed for the assessment of the biocompatibility of materials. Practice F 748 may provide guidance for the selection of appropriate methods for testing materials for other aspects of biocompatibility. Practice F 1984 provides guidance for testing solid materials for whole complement activation in human serum, but does not discriminate between the classical or alternative pathway of activation.

² Sepharose is a registered trademark of Pharmacia, Inc. (now GE Healthcare), Amersham Place, Little Chalfont, Buckinghamshire HP7 9NA, U.K.

Keywords:

blood compatibility

complement testing

alternative pathway

materials

medical devices

biocompatibility

About IHS
IHS (NYSE: IHS) is a leading global provider of critical technical information, decision-support tools and related services in a number of industries including aerospace and defense, automotive, construction, electronics, and energy. IHS serves customers ranging from large governments and multinational corporations to smaller companies and technical professionals in more than 100 countries. IHS been in business for more than 45 years and employ more than 2,300 people around the world.